#CDC #advisers #recommend #seasonal #Pfizer #RSV #shot
Pfizer’s new vaccine to protect infants against respiratory syncytial virus (RSV) by vaccinating their mothers late in pregnancy has received a limited recommendation from an expert panel advising the Centers for Disease Control and Prevention (CDC). The recommendation paves the way for a second product from Pfizer to soon enter the market, alongside Sanofi’s monoclonal antibody. The panel’s vote aims to simplify preventive measures for parents-to-be and healthcare providers, ensuring that babies are protected with one of the anti-RSV products, but not both at the same time. The Pfizer vaccine will be recommended for use during the period of September to January, whereas the Sanofi antibody will be used in the months following. The Pfizer vaccine will not be recommended for use in most of the US from February to August. The cost of the vaccine has raised concerns among committee members.